Trials / Not Yet Recruiting
Not Yet RecruitingNCT07026695
Transcutaneous Vagus Nerve Stimulation for Ventricular Arrhythmias
Transcutaneous Electrical Vagus Nerve Stimulation for Suppression of Ventricular Arrhythmias
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 72 (estimated)
- Sponsor
- University College, London · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Ventricular arrhythmias are abnormal heart rhythms that arise from the bottom chambers of the heart. They can cause debilitating symptoms when they occur intermittently (these are called premature ventricular ectopics or PVCs) and can be life-threatening when they occur continuously (called ventricular tachycardia or VT). These are the most common causes of sudden cardiac death, especially in patients with pre-existing heart disease. They can be a result of overactivation of the sympathetic nervous system, and in extreme circumstances, surgery to cut the nerve may be needed. A novel approach to target this nervous system using a transcutaneous electrical nerve stimulator (TENS) machine has successfully treated arrhythmias that come from the top chambers of the heart (atrial fibrillation). An ear clip is applied for an hour per day connected to a device (smaller than a phone) that can activate the parasympathetic nervous system (that counteracts the sympathetic nervous system). This is called Low-Level Tragus Stimulation (LLTS). Because it has been used for epilepsy for decades, we have evidence of a very high safety profile and tolerability. We plan to enrol 72 patients, 34 with many PVCs and 38 with VT, and randomise them to either first receive LLTS or first receive sham treatment (this will appear the same to the patient and researchers but without any meaningful vibrations being emitted in the sham group). Each patient will then swap over to the other treatment. We will compare whether the LLTS reduces the amount of ventricular arrhythmias during compared to the amount during the sham treatment period. We will use Holter monitors to measure the amount of PVCs after each period in the PVC group. VT patients have an implantable defibrillator that continuously monitors for VT episodes in this group. We will only enrol adults who can give informed consent, and study participation will not interfere with a patient's clinical treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | transcutaenous vagal nerve stimulation | Low level Stimulation of the Auricular Branch of the Vagal Nerve at the tragus |
| DEVICE | Sham transcutaenous vagal nerve stimulation | Sham treatment |
Timeline
- Start date
- 2025-06-15
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
- First posted
- 2025-06-18
- Last updated
- 2025-06-24
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT07026695. Inclusion in this directory is not an endorsement.